Entendendo Pólipos Nasais e Inflamação Tipo 2

Fale Conosco, Termos e Condições e Política de Privacidade

Referências

1. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
2. Heffler, Enrico, et al. “The Severe Asthma Network in Italy: Findings and Perspectives.” The Journal of Allergy and Clinical Immunology: In Practice 7.5 (2019): 1462-1468.
3. Shaw DE, et al Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308–1321.
4. Maio S, et al RItA: The Italian severe/uncontrolled asthma registry. Allergy. 2018;73:683–695.
5. Dharmage, Shyamali C., Jennifer Perret, and Adnan Custovic. Epidemiology of asthma in children and adults. Frontiers in paediatrics. 7 (2019): 246.
6. Network GA. The Global Asthma Report, Auckland, New Zealand. (2018).
7. Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, Janson C. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respiratory research. 2018 Dec 1;19(1):12.
8. von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. The Journal of Allergy and Clinical Immunology: In Practice. 2014 Nov 1;2(6):759-67.
9. Tay, T. R., Radhakrishna, N., Hore‐Lacy, F., Smith, C., Hoy, R., Dabscheck, E., & Hew, M. (2016). Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology, 21(8), 1384-1390.
10. Fletcher M, Hiles D. Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma form the UK. Prim Care Resp J. 2013;22(4):431-438.
11. Murphy KR, Meltzer EO, Blaiss MS, Nathan RA, Stoloff SW, Doherty DE. Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. In Allergy & Asthma Proceedings. 2012 Jan 1 (Vol. 33, No. 1).
12. Vennik J, Eyles C, Thomas M, Hopkins C, Little P, Blackshaw H, Schilder A, Boardman J, Philpott CM. Management strategies for chronic rhinosinusitis: a qualitative study of GP and ENT specialist views of current practice in the UK. BMJ open. 2018 Dec 1;8(12).
13. Andrews KL et al. Stigma: Still an Important Issue for Adults With Asthma. Journal of Asthma and Allergy Educators. Vol 4, Issue 4, 2013.
14. Reddel HK, et al. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7:e016688. Available at: https://bmjopen.bmj.com/content/7/9/e016688.full?ijkey=JWTMTG1oSaXXktC&keytype=ref.
15. GINA 2020 Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2020. Available at: https://ginasthma.org/gina-reports/. Last accessed April 2020.
16. Peters MC, Mekonnen ZK, Yuan S, et al. Measure of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388-394.
17. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017: 47(2): 161-175.
18. Fahy JV. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev lmmunol. 2015;15(1):57-65.
19. Global Initiative for Asthma (GINA). Pocket Guide for Asthma Management and Prevention. 2020. Available at: https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf. Last Accessed April 2020.
20. Behmanesh F, et al. Evaluation of anxiety and depression in mothers of children with asthma. Electron Physician. 2017:9(12);6058-6062.
21. Asthma and Allergy Foundation of America. My Life with Asthma Report. Available at http://www.aafa.org/my-life-with-asthma-report/. Last accessed October 2018.
22. Asthma and Allergy Foundation of America. My Life with Asthma Survey Overview. Available at: http://www.aafa.org/media/1684/my-life-with-asthma-in-2017-survey-findings-report.pdf. Last accessed October 2018.
23. Rand C, et al. Mediators of asthma outcomes. J Allergy Clin Immunol. 2012:129(3);136-141.
24. The European Academy of Allergy and Clinical Immunology (EAACI). Advocacy Manifesto: Tackling the Allergy Crisis in Europe - Concerted Policy Action Needed. Available at: http://www.eaaci.org/documents/EAACI_Advocacy_Manifesto.pdf. Last accessed October 2018.
25. European Respiratory Society. European Lung White Book, Chapter 2: The economic burden of lung disease. Available at: http://www.erswhitebook.org/files/public/Chapters/02_economics.pdf. Last accessed October 2018.
26. Daugherty J, et al. The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis. J Asthma. 2017 Sep;19:1-8.
27. Nunes C, Pereira AM, Morais-Ameida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.
28. Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. New England Journal of Medicine. 2017 Sep 7;377(10):965-76.
29. Chipps et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012 Aug;130(2):332-42.
30. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
31. Dunican EM, Fahy JV. The Role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc. 2015;12 Suppl 2:S144–S149.
32. Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347-58.
33. Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308(2):L130-40.
34. Matsusaka M, K Fukunaga, H Kabata, et al. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6(1):274-276.e2.
35. Fajt, M. L., & Wenzel, S. E. (2015). Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. Journal of Allergy and Clinical Immunology, 135(2), 299-310.
36. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464.
37. Khan A, Vandeplas G, Huynh TM, Joish VN, Mannent L, Tomassen P, Van Zele T, Cardell LO, Arebro J, Olze H, Foerster-Ruhrmann U. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42.
38. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, ten Brinke A, Bel EH. Severe adult-onset asthma: a distinct phenotype. Journal of allergy and clinical immunology. 2013 Aug 1;132(2):336-41.
39. Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, Mahdavinia M, Grammer LC, Hulse KE, Kern RC, Avila P. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. The Journal of Allergy and Clinical Immunology: In Practice. 2017 Jul 1;5(4):1061-70.
40. Gudziol V, Michel M, Sonnefeld C, Koschel D, Hummel T. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. European Archives of Oto-Rhino-Laryngology. 2017 Mar 1;274(3):1487-93
41. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.
42. Partridge, M. R. Delivering optimal care to the person with asthma: what are the key components and what do we mean by patient education? Eur Respir J. 1995: 8: 298-305.
43. Asthma Society of Canada. Severe Asthma - The Canadian Patient Journey: A study of the personal, social, medical and economic burden of Severe Asthma in Canada. Available at: https://www.asthma.ca/wp-content/uploads/2017/06/SAstudy.pdf Last accessed: December 2018. 1-8.

< Modal content>

Referências

Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12.
Dietz de Loos DA, Hopkins C, Fokkens WJ. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope. 2013;123(1):57-63.
SNOT-20 Copyright © 1996 by Jay F. Piccirillo, M.D., Washington University School of Medicine, St. Louis, Missouri SNOT-22 Developed from modification of SNOT-20 by National Comparative Audit of Surgery for Nasal Polyposis and Rhinosinusitis Royal College of Surgeons of England.
Bachert C, Gevaert E. Advances in rhinitis and rhinosinusitis in 2015. J Allergy Clin Immunol. 2016;138(5):1277-1283.
Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42.
Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27(6):473-478.
Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280-1289.
Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28(3):192-198.
Yasir M, Goyal A, Bansal P, et al. Corticosteroid Adverse Effects. [Updated 2020 Apr 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531462/.
DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-555.
Bassiouni A, Wormald PJ. Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope. 2013;123(1):36-41.
Wynn R, Har-El G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811-813.

Privacy Policy

WHY THIS DOCUMENT?

As part of its day to day operation, SANOFI provides access to a variety of tools and resources which are destined to provide information to all the individuals with whom it has business interactions with (patients and their relatives, participants to clinical trials, healthcare professionals, users of products and services, workers, etc.) regarding its activities.

Such tools and resources may be provided in various formats, including, more specifically in electronic format and by means of online electronic communications, including the website available at www.sanofi.com and any other website made available by SANOFI and to which this policy applies (hereinafter together the “Website”). In order to be able to provide them, SANOFI may need to collect and process Personal Data (as defined below) of their users.

SANOFI is fully committed to the protection of Personal Data and intends to provide you with all relevant information regarding the way in which SANOFI processes your Personal Data on the Website.

You will therefore find below all relevant information regarding the processing of Personal Data conducted on this Website. Please note that the content of this Website Privacy Policy may change from time to time, for instance in case of evolution of our processes or as a result of applicable law. Should these changes be objectively substantial and affect your rights or our obligations pertaining to the protection of Your Personal Data (and insofar as we have a means to contact you), we will notify you of the update by adequate means based on the information we may have collected.

However, we advise you to visit the page of this Website Privacy Policy regularly to verify any updates.

WHO IS RESPONSIBLE FOR THE PROCESSING OF PERSONAL DATA ON THIS WEBSITE (THE CONTROLLER)?

Genzyme Corporation is responsible for the processing of Personal Data of individuals using this website and therefore acts as the Controller:

Genzyme Corporation
50 Binney Street,
Cambridge, Massachusetts 02142
Tel.: + 1 (617) 252-7500

REMINDER: WHAT IS PERSONAL DATA & PROCESSING?

For the purposes of this Website Privacy Policy, Personal Data is any information relating to an identified or identifiable natural person, for all data processing carried out in the framework of its business and activities.

To make things clear, it is any information that relates to an individual. Such Personal Data can take the form of:

Basic identification information such as your name or date of birth;
Information that can be attributed to you directly or indirectly – such as a post on a social media;
Information which can be associated to you or your device such as, for instance, an IP address (i.e. the network address of your machine);
Etc.

In this respect, the notion of “processing” designates any action that is undertaken on your Personal Data such as, for instance:

Collection;
Storage;
Access;
Analysis;
Deletion;
Etc.

WHAT PERSONAL DATA DOES THIS WEBSITE COLLECT?

When operating, this Website may collect the following categories of Personal Data:

Connection data: any information regarding your connection and access to this Website (e.g. type of machine and browser used, timestamp of your connection, IP address, pages visited, etc.), browsing history
Location data: information that may be provided by your machine and browser about your location if you allow such information to be shared with Sanofi

Data relating to and data which may be collected by cookies: for more information about cookies, please click here to view our cookies policy (the cookies policy can be accessed by clicking the appropriate tab found here.) In addition, this website embeds poll functionality which asks survey questions regarding health conditions. The responses to the survey questions are collected anonymously and aggregated with other responses in order to show collective results. The poll is multiple-choice with no option for free text.

FOR WHAT PURPOSES DOES THIS WEBSITE COLLECT PERSONAL DATA?

Any processing of Personal Data must be implemented for a defined purpose. In this respect, the collection and processing of Personal Data on this Website is conducted for the following purposes:

To personalize your browsing experience: when using our services; ensure that our services are presented in the way that best suits you; understand your professional and personal interests in our content, products and services or other content and adapt our content to your needs and preferences; present you products and offers tailored to you.
To improve our products and services: identify usage trends and develop new products and services; understand how you and your device interacts with our services; track and respond to safety concerns; determine the effectiveness of our promotional campaigns, conduct surveys.

ON WHAT GROUNDS DOES THIS WEBSITE PROCESS YOUR PERSONAL DATA?

For the purposes of this Website, your Personal Data is only processed on the basis of:

your prior CONSENT: where you have clearly expressed your approval of SANOFI’s processing of your Personal Data. In practice, this will generally mean that SANOFI will ask you to sign a document, or to fill-in an online “opt-in” form or to follow any relevant procedure to allow you to be fully informed and then either clearly accept or refuse the envisaged Personal Data processing. By navigating this Website and, if relevant, consenting to the processing of your Personal Data using cookies (as per our cookies policy).
a contractual relationship between you and SANOFI: in such case, the processing of your Personal Data is generally necessary to the execution or the performance of the contract; this means that if you do not wish SANOFI to process your Personal Data in that context, SANOFI may or will be obliged to refuse to enter into such contract with you or will not be able to provide the products or services covered in this contract.
the “legitimate interest” of SANOFI in the sense of applicable data protection law. In such a case, SANOFI shall consider your fundamental rights and interests in determining whether the processing is legitimate and lawful.

HOW LONG IS THE PERSONAL DATA COLLECTED ON THIS WEBSITE RETAINED?

The Personal Data collected on this Website will be retained for the following periods, depending on the categories of Personal Data processed

Connection data: Session duration
Location data: Two years

data relating to and data which may be collected by cookies: Please see the cookies policy. The cookies policy can be accessed by clicking the appropriate tab found here.

WHO HAS ACCESS TO PERSONAL DATA

SANOFI may transfer your Personal Data both internally (i.e. to other SANOFI entities) and/or externally to third party service providers for the purposes outlined above.

Where such internal or external transfer of Personal Data implies the transfer of your Personal Data to a country providing a lower level of protection to Personal Data than generally afforded in your jurisdiction, SANOFI will ensure that a sufficient level of protection is provided to your Personal Data by implementing adequate safeguards such as the European Standard Contractual Clauses, the SANOFI Binding Corporate Rules or asking for your prior explicit consent.

YOUR RIGHTS: SANOFI WILL ENSURE THAT YOU CAN EXERCISE YOUR RIGHTS PERTAINING TO YOUR PERSONAL DATA

You can exercise your rights as provided by applicable data protection laws.

To that end, SANOFI informs you that you are entitled:

to have access upon simple request to your Personal Data – in which case you may receive a copy of such data (if requested), unless such data is made directly available to you, for instance within your personal account;
to obtain a rectification of your Personal Data should your Personal Data be inaccurate, incomplete or obsolete;
to obtain the deletion of your Personal Data in the situations set forth by applicable data protection law (‘right to be forgotten’);
to withdraw your consent to the processing of Persona Data processing without affecting the lawfulness of processing, where your Personal Data has been collected and processed on the basis of your consent;
to object to the processing of your Personal Data, where your Personal Data has been collected and processed on the basis of legitimate interests of SANOFI, in which case you will need to justify your request by explaining to us your particular situation;
to request a limitation of the processing of Personal Data processing in the situations set forth by applicable data protection law;
to receive your Personal Data for transmission from SANOFI to a third-party or to have your Personal Data directly transferred by SANOFI to the third-party of your choice, where technically feasible (data portability right allowed only where the processing is based on your consent)

If you would like to exercise any of these rights, please contact us as described in the “How to Contact Us” section below and we will take necessary steps to respond as soon as possible.

You may also file a complaint before a competent data protection authority regarding the processing of your Personal Data. While we suggest that you contact us beforehand, if you wish to exercise this right, you should contact directly the competent data protection authority.

HOW TO CONTACT US

SANOFI welcomes any questions or comments you may have regarding this Website Privacy Policy or its implementation. You can send any request pertaining to SANOFI’s use of your Personal Data to our Data Protection Officer at the following email address: privacy-office-global@sanofi.com.

You are now leaving TheNextBreath.com

Sanofi Genzyme and Regeneron do not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi Genzyme and Regeneron make no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi Genzyme and Regeneron necessarily endorse such website and/or database.

CANCEL CONTINUE

You are now leaving TheNextBreath.com

CANCEL CONTINUE

COOKIE POLICY

WHAT IS A COOKIE?

A cookie is a small data file stored on your computer or mobile device at the request of your browser when you visit this Website. The cookie allows the website to “remember” your actions or preference for a certain period of time. Most browsers allow cookies by default. However, users can set their browsers to refuse or remove them, if they wish.

There are different types of cookies:

Session cookies are deleted when you close your browser.
Permanent cookies remain on your device or computer until they expire or until you actively delete them. They enable certain information about your use to be recalled when you return to the website.

A cookie can temporarily store anonymous information about the use and users of a website.

WHAT COOKIES DOES SANOFI USE ON THIS WEBSITE?

Some cookies are necessary to be able to use the website, others allow customization and optimization of the content displayed, the collection of user preferences or the monitoring of the audience of the website, website errors and the securing of its access.

On our Website, we and our service providers use permanent cookies.

SANOFI is using cookies if you have properly consented through the cookies banner. If your consent is already given, the banner will not appear again as long as the cookie expiry term has not come to an end. If you do not want our Website to install cookies on your browser, you can disable cookies on the cookie settings page or by modifying your browser settings. In this case, certain pages of the Website may not function properly.

On this Website, we use cookies to measure audience and your use of the Website and to improve it.

ESSENTIAL COOKIES

These cookies are required for this Website to work, for example allowing users to remain logged into their account. Essential cookies cannot be disabled.

COOKIE NAME	COOKIE DESCRIPTION	COOKIE EXPIRY TERM
ASP.NET_SessionID	Preserves the visitor's session state across page requests.	Session
JSESSIONID	Used in J2EE web application which is used in session tracking	Session

MARKETING/PERFORMANCE COOKIES

COOKIE NAME	COOKIE DESCRIPTION	COOKIE EXPIRY TERM
_fbp	Used by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.	3 Months
_ga	This cookie name is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports.	2 years
_gat_UA	Pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.	1 minute
_gcl_au	Used by Google AdSense for experimenting with advertisement efficiency across websites using their services	Session
_gid	This cookie name is associated with Google Universal Analytics. Store and update a unique value for each page visited	24 hours
External_referer	This cookie is set by Twitter to identify and track the website visitor.	Session
fr	Used by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.	3 Months
Guest_id	This cookie is set by Twitter to identify and track the website visitor.	Session
Personalization_id	This cookie carries out information about how the end user uses the website and any advertising that the end user may have seen before visiting the said website.	Session

WHAT IF YOU DO NOT WANT COOKIES TO BE USED ON YOUR BROWSER?

You can block the use of cookies or remove cookies that are already installed on your browser. We draw your attention to the fact that disabling cookies may prevent you from accessing certain features on our Website and other websites.

You can set your browser to accept or reject all cookies, to be notified when a cookie is issued, to check its validity, duration and content and to periodically delete cookies.

You can also type “cookies” in your browser's help section to access the setup instructions.
For information about how to manage cookies on the browser of your mobile device, you will need to consult the device manual.

For more information about cookies, including how they are installed and how you can manage and delete them, visit www.allaboutcookies.org.

References

Emmerman et al. Prospective Multicenter Study of Relapse Following Treatment for Acute Asthma Among Adults Presenting to the Emergency Department. CHEST. 1999. 115(4):919-27
Price et al. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries. J Asthma. 2014. 51(2):127-35
Chipps et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012 Aug;130(2):332-42
Price et al. Asthma control and management in 8,000 European patients: the Recognise Asthma and Link to Symptom and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014. 12(24):14009
Sastre et al. Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. World Allergy Organ J. 2016. 4(9):13
Global Initiative for Asthma (GINA). Pocket Guide for Asthma Management and Prevention. 2019. Available at: https://ginasthma.org/2018-pocket-guide-for-asthma-management-and-prevention/. Last Accessed August 2019
Fletcher & Hiles. Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma from the UK. Prim Care Respir J. 2013. 22(4): 431-438
McDonald et al. Health-related quality of life burden in severe asthma. Med J Aust. 2018. 209(S2): S28-S33

Pólipos nasais me fazem sentir como se estivessem me sufocando.”

Veja como a ciência tem evoluido

Com pólipos nasais,
parece que meu
nariz está
sempre entupido ou escorrendo.”

Compreenda melhor
a causa da doença

Inflamação
Tipo 2

Asma

80%

Mais grave

Os fatos
sobre os
tratamentos tradicionais.

Corticoides não
promovem o controle duradouro
da doença.⁵

Pólipos nasais
frequentemente retornam
após a cirurgia.^11-13

Com pólipos nasais
estou sempre me afongando
em um mar de lenços.”

O tratamento da rinossinusite crônica com pólipos nasais é recomendado após a avaliação do médico especialista e pode incluir a prescrição de medicamentos para controlar o processo inflamatório.

Encontre um medico especialista utilizando as ferramentas de busca abaixo e utilize o guia de discussão para auxiliar na conversa com o seu médico.

MOVENDO O FUTURO, JUNTOS

#RepenseRespire

Pólipos nasais me fazem sentir como se estivessem me sufocando.”

Veja como a ciência tem evoluido

Com pólipos nasais,parece que meunariz estásempre entupido ou escorrendo.”

Compreenda melhora causa da doença

Inflamação Tipo 2